{"gene":"TFDP1","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":1993,"finding":"Human DP-1 (TFDP1) heterodimerizes with E2F-1 both in vivo and in vitro, and this heterodimer leads to enhanced binding to E2F DNA-binding sites and cooperative trans-activation of E2F-responsive promoters; the heterodimer is also required for stable interaction with pRB in vivo, and pRB inhibits transcriptional activity of the E2F-1/DP-1 complex.","method":"Co-immunoprecipitation (in vivo and in vitro), DNA-binding assays, trans-activation reporter assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (Co-IP, DNA-binding, transcriptional assays), replicated across multiple labs","pmids":["8405995"],"is_preprint":false},{"year":1993,"finding":"DP-1 (TFDP1) is a major sequence-specific DNA-binding component of the DRTF1/E2F transcription factor complex, including Rb- and p107-associated forms; its DNA-binding domain resembles that of E2F-1 and recognizes the same sequence.","method":"cDNA cloning, DNA-affinity purification, EMSA","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 — original isolation and characterization with multiple orthogonal methods","pmids":["8446173"],"is_preprint":false},{"year":1993,"finding":"DP-1 and E2F-1 exist as a heterodimeric DNA-binding complex in vivo, bind preferentially as a heterodimer to the E2F site, and interact synergistically in E2F site-dependent transcriptional activation in yeast and Drosophila cells.","method":"Co-immunoprecipitation, EMSA, transcriptional assays in yeast and Drosophila","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods across organisms, replicated","pmids":["8223441"],"is_preprint":false},{"year":1994,"finding":"DP-1 undergoes cell cycle-regulated phosphorylation with a phosphorylation-dependent mobility shift; a C-terminal region of DP-1 interacts with pRb and contributes to pRb binding efficiency in the context of the DP-1/E2F-1 heterodimer; the DP-1/E2F-1 heterodimer specifically interacts with adenovirus E4 orf 6/7 protein to produce cooperative DNA binding at two E2F sites.","method":"Immunoprecipitation, phosphopeptide analysis, in vitro binding assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods, direct in vitro and in vivo demonstration","pmids":["8039504"],"is_preprint":false},{"year":1994,"finding":"Cyclin A/CDK2 binds directly to E2F-1 (but not to DP-1) and phosphorylates the E2F-1/DP-1 complex, inhibiting its DNA-binding activity; the complex of cyclin A/CDK2 can be reconstituted from purified components with E2F-1/DP-1.","method":"In vitro reconstitution, kinase assay, in vitro and in vivo binding assays, 2D tryptic phosphopeptide mapping","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution from purified components plus in vivo corroboration","pmids":["7969176"],"is_preprint":false},{"year":1994,"finding":"Heterodimerization of E2F-1 and DP-1 is required for stable binding to adenovirus E4 (ORF6/7) protein; pRb binding to E2F-1/DP-1 prevents the formation of an E2F-1/DP-1/E4 complex; the interaction with E4 requires the C-terminal 20 amino acids of E4 and E2F-1 residues 284–358.","method":"Co-immunoprecipitation, in vitro binding assays, domain mapping/mutagenesis","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1–2 — domain mapping with mutagenesis and multiple binding assays","pmids":["8035503"],"is_preprint":false},{"year":1994,"finding":"The hydrophobic heptad repeat domain of DP-1 (amino acids 196–245) mediates heterodimerization with E2F-1's corresponding domain (amino acids 206–283); adenovirus E4 protein directly contacts the DP-1 hydrophobic heptad repeat domain and can dimerize, bridging two E2F-1/DP-1 heterodimers at the E2 promoter.","method":"Yeast two-hybrid assay, co-immunoprecipitation, domain mapping","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 2 — yeast two-hybrid and co-IP with defined domain mapping","pmids":["8207796"],"is_preprint":false},{"year":1994,"finding":"The same internal domains of E2F-1 and DP-1 required for E4-6/7 binding are also required for stable interaction with Rb, and E4-6/7 and Rb binding to E2F-1/DP-1 are mutually exclusive.","method":"In vitro binding assays, domain deletion mapping","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1–2 — direct in vitro binding with systematic domain mapping","pmids":["7933066"],"is_preprint":false},{"year":1995,"finding":"MDM2 makes functional contact with both E2F1 and DP1 using residues conserved with the p53 activation domain; in contrast to its repression of p53, MDM2 stimulates the transcriptional activation capacity of E2F1/DP1.","method":"Co-immunoprecipitation, transcriptional activation assays, domain mapping","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 — direct binding and functional assays, published in Nature","pmids":["7791903"],"is_preprint":false},{"year":1995,"finding":"E2F-1 and DP-1 physically complex with p53 both in vitro and in vivo; expression of both E2F1 and DP1 can inhibit p53-dependent transcription independently of MDM2, while wild-type p53 can inhibit E2F transcriptional activity.","method":"Co-immunoprecipitation, GST pulldown, transcriptional assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP with in vitro and in vivo validation","pmids":["8557038"],"is_preprint":false},{"year":1995,"finding":"E2F-1/DP-1 co-overexpression leads to greater loss of G1 regulation and significantly more apoptosis than E2F-1 alone; co-expression of DP-1 with E2F-1 increases endogenous p53 levels and overrides survival factors; induction of E2F-1/DP-1 increases expression and activity of cyclins A and E, and CDK2.","method":"Inducible expression, flow cytometry, apoptosis assays, immunoblotting","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — defined phenotypic readout with mechanistic targets identified","pmids":["8524253"],"is_preprint":false},{"year":1996,"finding":"CBP co-activator directly contacts the activation domain of E2F1 both in vitro and in vivo and stimulates E2F1/DP1 transcriptional activity; CBP-induced activation is abolished by E1A N-terminus competitor but not by CBP-binding-deficient E1A mutant.","method":"In vitro binding assay, co-immunoprecipitation, transcriptional assays, squelching experiments","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 — direct binding demonstrated both in vitro and in vivo with functional validation","pmids":["8932363"],"is_preprint":false},{"year":1996,"finding":"DP-1 mutants that retain E2F binding but lose DNA binding arrest cells in G1 by forming transcriptionally inactive E2F complexes; this G1 arrest can be rescued by co-expression of wild-type E2F or DP; functional domains of DP-1 required for dimerization and DNA binding were separated.","method":"Dominant-negative mutant transfection, flow cytometry, rescue experiments","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — dominant-negative approach with clear phenotypic readout and rescue, defining functional domains","pmids":["8668186"],"is_preprint":false},{"year":1996,"finding":"DP-1 associates with p53 in mammalian cell extracts; in vitro p53 interacts with an immunochemically distinct form of DP-1; p53 competes with E2F-1 for DP-1 binding, reducing DNA binding activity; a C-terminal region of DP-1 is required for the interaction with p53, and an N-terminal region of p53 distinct from that required for MDM2 binding is responsible.","method":"Co-immunoprecipitation, in vitro binding assays, domain mutagenesis, EMSA","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro and in vivo binding plus domain mutagenesis","pmids":["8816502"],"is_preprint":false},{"year":1996,"finding":"Induction of E2F-1/DP-1 results in increased expression and activity of cyclins A and E, and CDK2 prior to S-phase entry; increased phosphorylation of Rb follows, suggesting E2F feeds back on Rb; DP-1 alone (even with a VP16 transactivation domain) fails to promote cell cycle entry.","method":"Inducible expression system, immunoblotting, kinase assays, flow cytometry","journal":"Cell growth & differentiation","confidence":"High","confidence_rationale":"Tier 2 — systematic inducible expression with mechanistic target analysis","pmids":["8780882"],"is_preprint":false},{"year":1997,"finding":"p202, an interferon-inducible protein, inhibits E2F-4/DP-1-stimulated transcription; p202 associates with E2F-4 and pocket proteins p107 and p130, and inhibits sequence-specific DNA binding of E2F-4 both in complex with pocket proteins and in its free form.","method":"Transcriptional reporter assays, in vitro and in vivo binding assays, EMSA","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2–3 — single study with in vitro and in vivo binding and functional assays","pmids":["9233764"],"is_preprint":false},{"year":1998,"finding":"p53 inhibits transcription driven by the TFDP1 (DP-1) TATA-less promoter at the transcriptional level, with relative specificity for the DP1 promoter compared to the E2F1 promoter or unrelated promoters.","method":"Reporter gene assays, promoter deletion analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, functional assay but limited mechanistic follow-up","pmids":["9556576"],"is_preprint":false},{"year":1999,"finding":"Association of DP-1 with E2F subunits governs intracellular trafficking: DP-1 polypeptides that bind E2F-1 enter the nucleus, whereas those failing to associate with E2F accumulate in the cytoplasm as polyubiquitinated DP-1; E2F-1 binding prevents ubiquitin-dependent cytoplasmic degradation of DP-1.","method":"Immunolocalization, immunoprecipitation, cell fractionation, inducible expression","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (fractionation, Co-IP, localization) with functional consequence","pmids":["9989809"],"is_preprint":false},{"year":2001,"finding":"TRIP-Br1 and TRIP-Br2 proteins contact DP-1 and stimulate E2F-1/DP-1 transcriptional activity; TRIP-Br1 is a component of a multiprotein complex containing E2F-1 and DP-1; KRIP-1 potentiates TRIP-Br co-activation of E2F-1/DP-1; RB abolishes both baseline E2F-1/DP-1 activity and TRIP-Br co-activation.","method":"Co-immunoprecipitation, transcriptional assays, protein complex analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — Co-IP and transcriptional assays with multiple components","pmids":["11331592"],"is_preprint":false},{"year":2001,"finding":"Deregulated expression of DP-1 in mouse basal layer keratinocytes caused epidermal hyperplasia and hyperproliferation, and enhanced skin carcinogenesis in a two-stage chemical carcinogenesis assay; co-expression with E2F1 or E2F4 modestly enhanced proliferation and apoptosis.","method":"Transgenic mouse model, histology, two-stage carcinogenesis assay","journal":"Molecular carcinogenesis","confidence":"High","confidence_rationale":"Tier 2 — in vivo transgenic model with defined phenotypic readout","pmids":["11429786"],"is_preprint":false},{"year":2002,"finding":"ARF relocalizes DP-1 from the cytoplasm to the nucleolus when DP-1 is alone; however, the E2F1/DP-1 heterodimer is refractory to ARF-induced relocalization and remains in the nucleoplasm; ARF does not interact with the E2F1/DP-1 complex, and E2F1 is more stable in the presence of ARF when co-expressed with DP-1.","method":"Immunofluorescence localization, co-immunoprecipitation, stability assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including localization and stability assays","pmids":["12446760"],"is_preprint":false},{"year":2003,"finding":"Loss of Dp1 in mice leads to embryonic lethality due to failure of extra-embryonic (trophectoderm-derived) tissue development; specifically, expansion of the ectoplacental cone and chorion fail, and endoreduplication in trophoblast giant cells is compromised; inactivation of p53 cannot rescue Dp1-deficient embryonic lethality.","method":"Dp1 knockout mouse, histology, genetic rescue experiments","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — mouse knockout with defined cellular phenotype and epistasis test","pmids":["12588846"],"is_preprint":false},{"year":2004,"finding":"DP-1 activity is required for normal epidermal morphogenesis and ectoderm-to-epidermis transition; dominant-negative DP-1 inhibits E2F/DP-1 heterodimer DNA binding, DNA replication, and cyclin A expression; ChIP showed cyclin A promoter is bound predominantly by E2F-3 and E2F-4 complexes in proliferating keratinocytes.","method":"Dominant-negative expression in organotypic culture and embryonic explants, ChIP, immunoblotting","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — chromatin immunoprecipitation with functional dominant-negative assays and phenotypic readout","pmids":["15448153"],"is_preprint":false},{"year":2004,"finding":"Dp1-deficient embryonic stem cells can contribute strongly to most chimeric tissues, indicating that Dp1 is largely dispensable for embryonic (but not extraembryonic) development; abundance of DP2 protein does not increase in Dp1-deficient ES cells, and expression of an array of cell cycle genes is virtually unchanged.","method":"Chimeric mouse analysis, X-Gal staining, Western blotting, gene expression analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — genetic chimeric analysis with molecular characterization","pmids":["15282318"],"is_preprint":false},{"year":2005,"finding":"The crystal structure of an RbC–E2F1–DP1 complex reveals an intertwined heterodimer in which the marked box domains of both E2F1 and DP1 contact the Rb C-terminal domain (RbC); phosphorylation of RbC at S788/S795 directly destabilizes RbC–E2F/DP interactions, while phosphorylation at T821/T826 induces an intramolecular RbC–Rb pocket interaction that indirectly destabilizes the remaining contacts.","method":"X-ray crystallography, biochemical binding assays with phosphorylation-site mutants","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with phosphorylation-site mutagenesis and functional validation","pmids":["16360038"],"is_preprint":false},{"year":2005,"finding":"Two novel isoforms of human DP-1 (DP-1α and DP-1β) were identified; DP-1α lacks a portion of the C-terminal heterodimerization domain, shows significantly reduced binding to E2F1, does not translocate to the nucleus with E2F1, and acts as a dominant-negative regulator causing decreased transcriptional activity and G1 cell cycle arrest.","method":"Yeast two-hybrid, immunoprecipitation, immunofluorescence, transcriptional assays, flow cytometry","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods establishing isoform-specific mechanism","pmids":["15863509"],"is_preprint":false},{"year":2005,"finding":"ARF directly binds DP-1, and this binding inhibits the interaction between DP-1 and E2F1; ARF regulates DP-1 association with the dhfr target gene promoter (by ChIP); S-phase inhibition by ARF is preceded by inhibition of E2F-activated genes and occurs independently of p53 and Mdm2; the ARF–DP1 interaction is enhanced during oncogenic stress.","method":"Direct binding assay (GST pulldown), co-immunoprecipitation, ChIP, cell cycle analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 — direct binding assay plus ChIP plus functional cell cycle readout","pmids":["16135794"],"is_preprint":false},{"year":2008,"finding":"SOCS-3 directly interacts with the C-terminal region of DP-1 (requiring SOCS-3 residues 156–172) and is co-localized with DP-1 primarily in the cytoplasm; SOCS-3 inhibits E2F/DP-1 transcriptional activity under the cyclin-E promoter, inhibiting cell cycle progression; conversely, DP-1 almost completely abolishes the inhibitory action of SOCS-3 on JAK-STAT signaling.","method":"Yeast two-hybrid, co-immunoprecipitation, confocal microscopy, transcriptional assays, siRNA knockdown","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — yeast two-hybrid + co-IP + functional assays with domain mapping","pmids":["18687693"],"is_preprint":false},{"year":2010,"finding":"Cdk5 (in complex with p35) forms a complex with E2F1, excluding DP-1 cofactor from E2F1, thereby inhibiting E2F1 binding to promoters of cell cycle genes and suppressing cell cycle re-entry in post-mitotic neurons; this function does not require Cdk5 enzymatic activity.","method":"Co-immunoprecipitation, chromatin immunoprecipitation, kinase-dead mutant analysis","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — Co-IP and ChIP demonstrating complex formation and exclusion of DP-1","pmids":["20392944"],"is_preprint":false},{"year":2011,"finding":"Adenovirus E1A 13S isoform directly binds DP-1 and uses this interaction to recruit itself to E2F-regulated promoters, activating E2F-responsive gene expression independently of pRb-family binding; this binding is through a direct interaction with DP-1 (not E2F), and E1A 13S (but not 12S) enhances E2F4 occupancy at E2F sites.","method":"Co-immunoprecipitation, ChIP, reporter assays, domain mapping","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 2 — direct binding demonstrated with ChIP and functional transcriptional assays","pmids":["21715488"],"is_preprint":false},{"year":2015,"finding":"Kbtbd5 directly interacts with DP-1 (via its dimerization domain) and promotes ubiquitination and degradation of DP-1, thereby inhibiting E2F1-DP-1 transcriptional activity; loss of Kbtbd5 in mice causes increased E2F1 target gene expression and apoptosis in skeletal muscle; breeding into E2F1 null background rescues the lethal phenotype.","method":"Yeast two-hybrid, GST pulldown, ubiquitination assay, knockout mouse, genetic epistasis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — direct binding assay + ubiquitination assay + genetic epistasis in vivo","pmids":["25940086"],"is_preprint":false},{"year":2016,"finding":"COMMD9 interacts with TFDP1 through its COMM domain, requiring the DNA-binding domain of TFDP1; COMMD9 knockdown attenuates TFDP1/E2F1 transcriptional activity and enhances p53 signaling in NSCLC cells.","method":"Co-immunoprecipitation, siRNA knockdown, transcriptional assays","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP with functional assays but single lab, single binding method","pmids":["27871936"],"is_preprint":false},{"year":2016,"finding":"Knockdown of TFDP1 inhibits E2F1-mediated PITX1 promoter activity and mRNA transcription in articular chondrocytes; E2F1 directly binds GC-rich elements in the PITX1 promoter; TFDP1 knockdown reduces expression of PITX1, BRCA1, CDKN1A, and RAD51 in mid-stage OA chondrocytes.","method":"siRNA knockdown, luciferase reporter assay, ChIP, DNA pulldown, qRT-PCR","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — siRNA knockdown combined with ChIP and promoter assays","pmids":["27802335"],"is_preprint":false},{"year":2019,"finding":"KPNA2 (karyopherin α2) imports E2F1 and TFDP1 into the nucleus; upon KPNA2 knockdown, E2F1 and TFDP1 are retained in the cytoplasm, leading to reduced STMN1 (stathmin) expression; the KPNA2–E2F1/TFDP1–STMN1 axis regulates tumor cell migration and colony formation in HCC.","method":"siRNA knockdown, subcellular fractionation, co-immunoprecipitation, ChIP, proteomics (LC-MS/MS)","journal":"Cell communication and signaling : CCS","confidence":"High","confidence_rationale":"Tier 2 — proteomic screen + fractionation + Co-IP + ChIP demonstrating nuclear transport mechanism","pmids":["31783876"],"is_preprint":false},{"year":2022,"finding":"KDM6B (an H3K27me3 demethylase) interacts with TFDP1, which normally binds to the promoter of Trp53 to activate Trp53 expression in palatal mesenchymal cells; without KDM6B, TFDP1 cannot activate Trp53, leading to complete cleft palate; H3K27me3 on the Trp53 promoter is antagonistically controlled by KDM6B and EZH2.","method":"Conditional knockout mouse, ChIP, co-immunoprecipitation, promoter analysis, histology","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with ChIP and protein interaction data demonstrating mechanism","pmids":["35212626"],"is_preprint":false},{"year":2023,"finding":"The TFDP1 gene is a target of deregulated E2F1: overexpression of E2F1 and pRb inactivation (by adenovirus E1a) induce TFDP1 gene expression in normal fibroblasts; deregulated (but not physiological) E2F1 binds GC-rich elements in the TFDP1 promoter (by ChIP); DP1 knockdown enhances ARF gene expression, suggesting TFDP1 induction by deregulated E2F acts as a failsafe feedback mechanism.","method":"E2F1 overexpression, adenovirus E1a, promoter deletion analysis, ChIP, shRNA knockdown, qRT-PCR","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus promoter mutagenesis plus functional knockdown, defining a regulatory circuit","pmids":["37141667"],"is_preprint":false},{"year":2024,"finding":"Genome-wide CRISPR/ATAC-see screening identified TFDP1 as a modulator of global chromatin accessibility; TFDP1 knockout reduces chromatin accessibility by transcriptionally regulating canonical histones.","method":"Genome-wide CRISPR screen, ATAC-see, ATAC-seq, TFDP1 knockout","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — genome-wide unbiased screen with ATAC-seq validation and KO mechanistic follow-up","pmids":["38361031"],"is_preprint":false}],"current_model":"TFDP1 encodes DP-1, which obligatorily heterodimerizes with E2F-family proteins (primarily through hydrophobic heptad repeat and marked box domains) to form the active E2F/DP-1 transcription factor complex; this complex binds E2F DNA sites to activate S-phase genes (cyclins A/E, CDK2, DHFR, etc.) and is regulated by pRb (which directly contacts both E2F1 and DP-1 marked box domains to repress activity), cyclin A/CDK2 phosphorylation (which inhibits DNA binding), ARF (which directly binds free DP-1 to disrupt E2F1/DP-1 heterodimerization), ubiquitin-mediated degradation (prevented by E2F-1 association, which promotes nuclear entry), co-activators (CBP, MDM2, TRIP-Br), and co-repressors (p53, SOCS-3, p202); nuclear import of the E2F1/TFDP1 complex is mediated by KPNA2, and TFDP1 itself is transcriptionally induced by deregulated E2F1 as a feedback mechanism; additionally, TFDP1 modulates global chromatin accessibility through transcriptional regulation of canonical histones."},"narrative":{"teleology":[{"year":1993,"claim":"Identification of DP-1 as an obligate heterodimeric partner of E2F-1 resolved the long-standing question of how high-affinity, sequence-specific E2F DNA binding and transcriptional activation are achieved, and established that the resulting heterodimer is a target of pRb-mediated repression.","evidence":"Co-immunoprecipitation, EMSA, and transcriptional reporter assays in mammalian, yeast, and Drosophila cells","pmids":["8405995","8446173","8223441"],"confidence":"High","gaps":["Stoichiometry and affinity of the heterodimer not quantified","Whether DP-1 contributes transactivation function independently of E2F was unclear","In vivo physiological requirement not yet tested"]},{"year":1994,"claim":"Mapping the hydrophobic heptad repeat domain (DP-1 aa 196–245) as the heterodimerization interface and demonstrating cell-cycle-dependent DP-1 phosphorylation and cyclin A/CDK2-mediated inhibition of DNA binding defined the structural and regulatory logic governing E2F/DP activity.","evidence":"Yeast two-hybrid, domain deletion mapping, in vitro kinase assays with purified components, phosphopeptide analysis","pmids":["8207796","8039504","7969176"],"confidence":"High","gaps":["Precise phosphorylation sites on DP-1 responsible for DNA-binding inhibition not mapped","Whether cyclin A/CDK2 phosphorylates DP-1 directly or only E2F-1 in the heterodimer was unresolved"]},{"year":1995,"claim":"Discovery that MDM2 stimulates and p53 inhibits E2F1/DP-1 transcriptional activity, and that E2F-1/DP-1 overexpression induces p53 and apoptosis, placed the E2F/DP complex at the intersection of proliferation and apoptosis pathways.","evidence":"Co-immunoprecipitation, GST pulldown, transcriptional assays, inducible expression with flow cytometry and apoptosis measurement","pmids":["7791903","8557038","8524253"],"confidence":"High","gaps":["Physiological relevance of MDM2 co-activation versus p53 repression not resolved in normal cells","Whether DP-1 directly contacts MDM2 or p53 independently of E2F-1 needed clarification"]},{"year":1996,"claim":"Demonstration that dominant-negative DP-1 mutants retaining E2F binding but lacking DNA-binding activity arrest cells in G1, and that p53 directly competes with E2F-1 for DP-1 binding, established DP-1 as a rate-limiting factor for E2F-dependent S-phase entry.","evidence":"Dominant-negative transfection with flow cytometry, rescue experiments, domain mutagenesis, and EMSA competition assays","pmids":["8668186","8816502"],"confidence":"High","gaps":["Whether p53-DP-1 complex has a function beyond sequestration was unknown","In vivo relevance of p53-DP-1 competition not tested genetically"]},{"year":1999,"claim":"Showing that E2F-1 binding rescues DP-1 from cytoplasmic polyubiquitination and promotes its nuclear entry revealed that subcellular partitioning and protein stability are coupled to heterodimerization status.","evidence":"Immunolocalization, cell fractionation, immunoprecipitation of ubiquitinated species, inducible expression","pmids":["9989809"],"confidence":"High","gaps":["The E3 ubiquitin ligase responsible for DP-1 cytoplasmic degradation was not identified","Whether regulated deubiquitination plays a role was unknown"]},{"year":2003,"claim":"Dp1 knockout in mice causing embryonic lethality due to failed trophoblast expansion and endoreduplication — not rescued by p53 loss — demonstrated an essential, p53-independent developmental role for DP-1 in extra-embryonic tissues.","evidence":"Dp1 knockout mouse, histological analysis, p53 genetic rescue cross","pmids":["12588846"],"confidence":"High","gaps":["Which E2F partner(s) mediate the extra-embryonic requirement was not determined","Molecular targets of E2F/DP in endoreduplication not identified","Why embryonic tissues tolerate Dp1 loss (later shown via chimera analysis) needed explanation"]},{"year":2004,"claim":"Chimeric mouse analysis showing that Dp1-null ES cells contribute normally to most embryonic tissues, without compensatory DP-2 upregulation, revealed that DP-1 is largely dispensable for embryonic somatic cell proliferation, restricting its essential role to extra-embryonic lineages.","evidence":"Dp1-null ES cell chimeras, X-Gal staining, Western blot, expression profiling","pmids":["15282318"],"confidence":"High","gaps":["Whether DP-2 functionally compensates despite unchanged protein levels was not formally tested","Adult tissue-specific requirements not examined"]},{"year":2005,"claim":"The crystal structure of the RbC–E2F1–DP1 complex revealed that the marked box domains of both E2F1 and DP1 directly contact the Rb C-terminal domain, and phosphorylation at specific Rb sites destabilizes these contacts, providing an atomic-level mechanism for CDK-driven E2F/DP release.","evidence":"X-ray crystallography with phosphorylation-site mutagenesis and biochemical binding assays","pmids":["16360038"],"confidence":"High","gaps":["Structure of full-length DP-1 or of DP-1 with other E2F family members not determined","Dynamics of the release in vivo not captured"]},{"year":2005,"claim":"Direct binding of ARF to DP-1 that disrupts E2F1/DP-1 heterodimerization independently of p53/Mdm2, and identification of dominant-negative DP-1 isoforms (DP-1α), defined two distinct mechanisms that restrain E2F/DP activity by targeting DP-1 availability.","evidence":"GST pulldown, ChIP at dhfr promoter, cell cycle analysis in p53-null cells; yeast two-hybrid and immunofluorescence for isoform characterization","pmids":["16135794","15863509"],"confidence":"High","gaps":["Physiological abundance and tissue distribution of DP-1α isoform unknown","Whether ARF-DP-1 binding occurs at specific genomic loci genome-wide not tested"]},{"year":2015,"claim":"Identification of Kbtbd5 as a direct E3 ligase adapter that ubiquitinates DP-1 via its dimerization domain, with genetic epistasis showing that Kbtbd5-null lethality is rescued by E2F1 loss, established a tissue-specific ubiquitin-dependent mechanism controlling E2F/DP activity in skeletal muscle.","evidence":"Yeast two-hybrid, GST pulldown, ubiquitination assay, Kbtbd5 knockout mouse, E2F1-null genetic rescue","pmids":["25940086"],"confidence":"High","gaps":["Whether Kbtbd5 acts as the Cullin adapter or a direct RING E3 was not fully clarified","Other tissues regulated by Kbtbd5-DP-1 axis not explored"]},{"year":2019,"claim":"Demonstration that KPNA2 mediates nuclear import of the E2F1/TFDP1 complex, with KPNA2 depletion causing cytoplasmic retention and loss of target gene (STMN1) expression, defined the nuclear transport pathway for E2F/DP.","evidence":"siRNA knockdown, subcellular fractionation, co-immunoprecipitation, ChIP, LC-MS/MS proteomics in HCC cells","pmids":["31783876"],"confidence":"High","gaps":["Whether KPNA2 recognizes a classical NLS on E2F1, DP-1, or both was not mapped","Redundancy with other karyopherin-α isoforms not tested"]},{"year":2023,"claim":"Showing that deregulated E2F1 transcriptionally induces TFDP1 itself via GC-rich promoter elements, while DP-1 knockdown derepresses ARF, revealed a positive-feedback/failsafe circuit in which excessive E2F activity amplifies DP-1 but simultaneously triggers ARF-mediated restraint.","evidence":"E2F1 overexpression, adenovirus E1a, ChIP on TFDP1 promoter, shRNA knockdown, qRT-PCR in fibroblasts","pmids":["37141667"],"confidence":"High","gaps":["Whether this feedback circuit operates in all cell types or is context-specific was not determined","Quantitative thresholds for feedback engagement not defined"]},{"year":2024,"claim":"A genome-wide CRISPR/ATAC-see screen identified TFDP1 as a regulator of global chromatin accessibility beyond classical E2F target genes, acting through transcriptional control of canonical histone expression, expanding TFDP1's role from cell cycle gene regulation to a broader chromatin organizer.","evidence":"Genome-wide CRISPR screen, ATAC-see, ATAC-seq, TFDP1 knockout with expression analysis","pmids":["38361031"],"confidence":"High","gaps":["Which E2F partner(s) cooperate with DP-1 for histone gene regulation not identified","Whether reduced chromatin accessibility is a direct or indirect consequence of histone loss not fully resolved","Impact on heterochromatin versus euchromatin domains not dissected"]},{"year":null,"claim":"Key unresolved questions include the full-length structure of DP-1 in complex with different E2F family members, the complete repertoire of E3 ligases targeting DP-1 across tissues, the genome-wide interplay between ARF-DP-1 and Rb-E2F/DP regulatory arms, and whether DP-1's chromatin accessibility function via histone regulation is separable from its canonical role in activating S-phase genes.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length DP-1 structure available","Tissue-specific E3 ligase landscape for DP-1 degradation uncharacterized","Genome-wide ARF-DP-1 binding sites not mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,2,12,22]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,10,14,32,36]}],"localization":[{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[17,20,33]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[17,20,27]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[17,25,33]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[10,12,14,22,26]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,11,32,35,36]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[36]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[10,30]}],"complexes":["E2F/DP heterodimer","E2F/DP/Rb complex","E2F/DP/p107 complex"],"partners":["E2F1","RB1","CDKN2A","KPNA2","MDM2","TP53","KBTBD5","SOCS3"],"other_free_text":[]},"mechanistic_narrative":"TFDP1 encodes the transcription factor DP-1, an obligate heterodimerization partner of E2F-family proteins that together form the sequence-specific DNA-binding E2F/DP complex governing S-phase gene expression and cell cycle progression [PMID:8405995, PMID:8446173, PMID:8223441]. Heterodimerization occurs through the hydrophobic heptad repeat and marked box domains; the resulting complex activates transcription of cyclins A and E, CDK2, and DHFR, and is negatively regulated by pRb (which contacts both E2F1 and DP-1 marked box domains), cyclin A/CDK2-mediated phosphorylation that inhibits DNA binding, ARF (which directly binds free DP-1 to disrupt E2F1/DP-1 heterodimerization independently of p53), and Kbtbd5-mediated ubiquitination and degradation of DP-1 [PMID:16360038, PMID:7969176, PMID:16135794, PMID:25940086]. Nuclear import of the E2F1/TFDP1 complex requires KPNA2, and unpartnered DP-1 is retained in the cytoplasm and targeted for ubiquitin-dependent degradation [PMID:31783876, PMID:9989809]. Beyond canonical cell cycle gene regulation, TFDP1 modulates global chromatin accessibility through transcriptional control of canonical histones [PMID:38361031]."},"prefetch_data":{"uniprot":{"accession":"Q14186","full_name":"Transcription factor Dp-1","aliases":["DRTF1-polypeptide 1","DRTF1","E2F dimerization partner 1"],"length_aa":410,"mass_kda":45.1,"function":"Can stimulate E2F-dependent transcription. Binds DNA cooperatively with E2F family members through the E2 recognition site, 5'-TTTC[CG]CGC-3', found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication (PubMed:7739537, PubMed:8405995). The E2F1:DP complex appears to mediate both cell proliferation and apoptosis. Blocks adipocyte differentiation by repressing CEBPA binding to its target gene promoters (PubMed:20176812)","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q14186/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/TFDP1","classification":"Common Essential","n_dependent_lines":871,"n_total_lines":1208,"dependency_fraction":0.7210264900662252},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HSPA8","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/TFDP1","total_profiled":1310},"omim":[{"mim_id":"621288","title":"LIN52 DREAM MUVB CORE COMPLEX COMPONENT; LIN52","url":"https://www.omim.org/entry/621288"},{"mim_id":"621287","title":"LIN37 DREAM MUVB CORE COMPLEX COMPONENT; LIN37","url":"https://www.omim.org/entry/621287"},{"mim_id":"617851","title":"SERTA DOMAIN-CONTAINING PROTEIN 2; SERTAD2","url":"https://www.omim.org/entry/617851"},{"mim_id":"617850","title":"SERTA DOMAIN-CONTAINING PROTEIN 1; SERTAD1","url":"https://www.omim.org/entry/617850"},{"mim_id":"613367","title":"LIN54, C. ELEGANS, HOMOLOG OF; LIN54","url":"https://www.omim.org/entry/613367"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Nuclear membrane","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":154.7}],"url":"https://www.proteinatlas.org/search/TFDP1"},"hgnc":{"alias_symbol":["Dp-1","DRTF1","DP1","DILC"],"prev_symbol":[]},"alphafold":{"accession":"Q14186","domains":[{"cath_id":"1.10.10.10","chopping":"115-194","consensus_level":"high","plddt":89.8495,"start":115,"end":194},{"cath_id":"1.20.140.80","chopping":"199-338","consensus_level":"medium","plddt":94.5087,"start":199,"end":338}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14186","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14186-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14186-F1-predicted_aligned_error_v6.png","plddt_mean":69.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TFDP1","jax_strain_url":"https://www.jax.org/strain/search?query=TFDP1"},"sequence":{"accession":"Q14186","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14186.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14186/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14186"}},"corpus_meta":[{"pmid":"8405995","id":"PMC_8405995","title":"Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation.","date":"1993","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8405995","citation_count":468,"is_preprint":false},{"pmid":"7791903","id":"PMC_7791903","title":"Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7791903","citation_count":461,"is_preprint":false},{"pmid":"8203017","id":"PMC_8203017","title":"DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control.","date":"1994","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/8203017","citation_count":349,"is_preprint":false},{"pmid":"7969176","id":"PMC_7969176","title":"Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7969176","citation_count":262,"is_preprint":false},{"pmid":"26812074","id":"PMC_26812074","title":"Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis.","date":"2016","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/26812074","citation_count":256,"is_preprint":false},{"pmid":"8446173","id":"PMC_8446173","title":"A new component of the transcription factor DRTF1/E2F.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8446173","citation_count":256,"is_preprint":false},{"pmid":"8223441","id":"PMC_8223441","title":"Functional synergy between DP-1 and E2F-1 in the cell cycle-regulating transcription factor DRTF1/E2F.","date":"1993","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8223441","citation_count":247,"is_preprint":false},{"pmid":"16360038","id":"PMC_16360038","title":"Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16360038","citation_count":206,"is_preprint":false},{"pmid":"12029633","id":"PMC_12029633","title":"TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.","date":"2002","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12029633","citation_count":161,"is_preprint":false},{"pmid":"8524253","id":"PMC_8524253","title":"E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8524253","citation_count":156,"is_preprint":false},{"pmid":"15659218","id":"PMC_15659218","title":"Prostaglandin D2 mediates neuronal protection via the DP1 receptor.","date":"2005","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15659218","citation_count":141,"is_preprint":false},{"pmid":"17965752","id":"PMC_17965752","title":"The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses.","date":"2007","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17965752","citation_count":133,"is_preprint":false},{"pmid":"22480736","id":"PMC_22480736","title":"Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist.","date":"2012","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22480736","citation_count":130,"is_preprint":false},{"pmid":"8668186","id":"PMC_8668186","title":"Expression of dominant-negative mutant DP-1 blocks cell cycle progression in G1.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8668186","citation_count":123,"is_preprint":false},{"pmid":"8932363","id":"PMC_8932363","title":"The CBP co-activator stimulates E2F1/DP1 activity.","date":"1996","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/8932363","citation_count":106,"is_preprint":false},{"pmid":"28612233","id":"PMC_28612233","title":"Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives.","date":"2017","source":"Drugs","url":"https://pubmed.ncbi.nlm.nih.gov/28612233","citation_count":104,"is_preprint":false},{"pmid":"11331592","id":"PMC_11331592","title":"TRIP-Br: a novel family of PHD zinc finger- and bromodomain-interacting proteins that regulate the transcriptional activity of E2F-1/DP-1.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11331592","citation_count":102,"is_preprint":false},{"pmid":"23624557","id":"PMC_23624557","title":"Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-DP1 receptor paracrine axis.","date":"2013","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23624557","citation_count":97,"is_preprint":false},{"pmid":"8039504","id":"PMC_8039504","title":"DP-1: a cell cycle-regulated and phosphorylated component of transcription factor DRTF1/E2F which is functionally important for recognition by pRb and the adenovirus E4 orf 6/7 protein.","date":"1994","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8039504","citation_count":96,"is_preprint":false},{"pmid":"8557038","id":"PMC_8557038","title":"Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1.","date":"1995","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8557038","citation_count":92,"is_preprint":false},{"pmid":"1352290","id":"PMC_1352290","title":"Molecular cloning of rat prostate transglutaminase complementary DNA. The major androgen-regulated protein DP1 of rat dorsal prostate and coagulating gland.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1352290","citation_count":83,"is_preprint":false},{"pmid":"20392944","id":"PMC_20392944","title":"Cdk5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 complex.","date":"2010","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20392944","citation_count":82,"is_preprint":false},{"pmid":"19995430","id":"PMC_19995430","title":"Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes.","date":"2009","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/19995430","citation_count":81,"is_preprint":false},{"pmid":"17549007","id":"PMC_17549007","title":"Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease.","date":"2007","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17549007","citation_count":72,"is_preprint":false},{"pmid":"9379901","id":"PMC_9379901","title":"The lytic enzyme of the pneumococcal phage Dp-1: a chimeric lysin of intergeneric origin.","date":"1997","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/9379901","citation_count":70,"is_preprint":false},{"pmid":"9233764","id":"PMC_9233764","title":"Inhibition of E2F-4/DP-1-stimulated transcription by p202.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9233764","citation_count":65,"is_preprint":false},{"pmid":"31917615","id":"PMC_31917615","title":"Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling.","date":"2020","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31917615","citation_count":61,"is_preprint":false},{"pmid":"12446760","id":"PMC_12446760","title":"Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12446760","citation_count":61,"is_preprint":false},{"pmid":"8780882","id":"PMC_8780882","title":"The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis.","date":"1996","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/8780882","citation_count":58,"is_preprint":false},{"pmid":"7478568","id":"PMC_7478568","title":"A new member of the DP family, DP-3, with distinct protein products suggests a regulatory role for alternative splicing in the cell cycle transcription factor DRTF1/E2F.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7478568","citation_count":57,"is_preprint":false},{"pmid":"28630327","id":"PMC_28630327","title":"Virus-induced inflammasome activation is suppressed by prostaglandin D2/DP1 signaling.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28630327","citation_count":55,"is_preprint":false},{"pmid":"12588846","id":"PMC_12588846","title":"Dp1 is required for extra-embryonic development.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12588846","citation_count":55,"is_preprint":false},{"pmid":"8035503","id":"PMC_8035503","title":"Heterodimerization of the transcription factors E2F-1 and DP-1 is required for binding to the adenovirus E4 (ORF6/7) protein.","date":"1994","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/8035503","citation_count":54,"is_preprint":false},{"pmid":"8816502","id":"PMC_8816502","title":"Functional interaction between DP-1 and p53.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8816502","citation_count":53,"is_preprint":false},{"pmid":"27871936","id":"PMC_27871936","title":"COMMD9 promotes TFDP1/E2F1 transcriptional activity via interaction with TFDP1 in non-small cell lung cancer.","date":"2016","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/27871936","citation_count":51,"is_preprint":false},{"pmid":"15556157","id":"PMC_15556157","title":"Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis.","date":"2004","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15556157","citation_count":51,"is_preprint":false},{"pmid":"14618416","id":"PMC_14618416","title":"Association of over-expressed TFDP1 with progression of hepatocellular carcinomas.","date":"2003","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14618416","citation_count":50,"is_preprint":false},{"pmid":"19748656","id":"PMC_19748656","title":"Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis.","date":"2009","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19748656","citation_count":50,"is_preprint":false},{"pmid":"15590767","id":"PMC_15590767","title":"Effects of prostaglandin D2, 15-deoxy-Delta12,14-prostaglandin J2, and selective DP1 and DP2 receptor agonists on pulmonary infiltration of eosinophils in Brown Norway rats.","date":"2004","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/15590767","citation_count":50,"is_preprint":false},{"pmid":"32066912","id":"PMC_32066912","title":"miR-4711-5p regulates cancer stemness and cell cycle progression via KLF5, MDM2 and TFDP1 in colon cancer cells.","date":"2020","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32066912","citation_count":49,"is_preprint":false},{"pmid":"25323233","id":"PMC_25323233","title":"Prostaglandin D2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events.","date":"2014","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/25323233","citation_count":47,"is_preprint":false},{"pmid":"21097633","id":"PMC_21097633","title":"Genome annotation and intraviral interactome for the Streptococcus pneumoniae virulent phage Dp-1.","date":"2010","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/21097633","citation_count":46,"is_preprint":false},{"pmid":"26940376","id":"PMC_26940376","title":"A novel alkaline keratinase from Bacillus subtilis DP1 with potential utility in cosmetic formulation.","date":"2016","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/26940376","citation_count":43,"is_preprint":false},{"pmid":"16135794","id":"PMC_16135794","title":"ARF directly binds DP1: interaction with DP1 coincides with the G1 arrest function of ARF.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16135794","citation_count":42,"is_preprint":false},{"pmid":"21715488","id":"PMC_21715488","title":"Adenovirus E1A directly targets the E2F/DP-1 complex.","date":"2011","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/21715488","citation_count":42,"is_preprint":false},{"pmid":"35354317","id":"PMC_35354317","title":"DP1 (Prostaglandin D2 Receptor 1) Activation Protects Against Vascular Remodeling and Vascular Smooth Muscle Cell Transition to Myofibroblasts in Angiotensin II-Induced Hypertension in Mice.","date":"2022","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/35354317","citation_count":42,"is_preprint":false},{"pmid":"17573924","id":"PMC_17573924","title":"PGD(2) DP1 receptor protects brain from ischemia-reperfusion injury.","date":"2007","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17573924","citation_count":41,"is_preprint":false},{"pmid":"20556744","id":"PMC_20556744","title":"Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer.","date":"2010","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20556744","citation_count":36,"is_preprint":false},{"pmid":"20308056","id":"PMC_20308056","title":"Mast cell-derived prostaglandin D2 controls hyaluronan synthesis in human orbital fibroblasts via DP1 activation: implications for thyroid eye disease.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20308056","citation_count":35,"is_preprint":false},{"pmid":"31783876","id":"PMC_31783876","title":"Karyopherin α2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer.","date":"2019","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/31783876","citation_count":34,"is_preprint":false},{"pmid":"31592114","id":"PMC_31592114","title":"Long noncoding RNA lnc-DILC stabilizes PTEN and suppresses clear cell renal cell carcinoma progression.","date":"2019","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/31592114","citation_count":34,"is_preprint":false},{"pmid":"30944206","id":"PMC_30944206","title":"LncRNA DILC participates in rheumatoid arthritis by inducing apoptosis of fibroblast-like synoviocytes and down-regulating IL-6.","date":"2019","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/30944206","citation_count":33,"is_preprint":false},{"pmid":"25474649","id":"PMC_25474649","title":"Dexamethasone protects neonatal hypoxic-ischemic brain injury via L-PGDS-dependent PGD2-DP1-pERK signaling pathway.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25474649","citation_count":33,"is_preprint":false},{"pmid":"8537434","id":"PMC_8537434","title":"Functional conservation of the cell cycle-regulating transcription factor DRTF1/E2F and its pathway of control in Drosophila melanogaster.","date":"1995","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/8537434","citation_count":33,"is_preprint":false},{"pmid":"20640551","id":"PMC_20640551","title":"Prostaglandin D2 DP1 receptor is beneficial in ischemic stroke and in acute exicitotoxicity in young and old mice.","date":"2010","source":"Age (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/20640551","citation_count":33,"is_preprint":false},{"pmid":"32510145","id":"PMC_32510145","title":"Inhibition of lncRNA DILC attenuates neuropathic pain via the SOCS3/JAK2/STAT3 pathway.","date":"2020","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/32510145","citation_count":31,"is_preprint":false},{"pmid":"8207796","id":"PMC_8207796","title":"Interacting domains of E2F1, DP1, and the adenovirus E4 protein.","date":"1994","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/8207796","citation_count":31,"is_preprint":false},{"pmid":"31893939","id":"PMC_31893939","title":"DP1 Activation Reverses Age-Related Hypertension Via NEDD4L-Mediated T-Bet Degradation in T Cells.","date":"2020","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/31893939","citation_count":30,"is_preprint":false},{"pmid":"7933066","id":"PMC_7933066","title":"Mutually exclusive interaction of the adenovirus E4-6/7 protein and the retinoblastoma gene product with internal domains of E2F-1 and DP-1.","date":"1994","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/7933066","citation_count":30,"is_preprint":false},{"pmid":"31069838","id":"PMC_31069838","title":"lncRNA DILC is downregulated in osteoarthritis and regulates IL-6 expression in chondrocytes.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31069838","citation_count":28,"is_preprint":false},{"pmid":"29630407","id":"PMC_29630407","title":"The endogenous bioactive lipid prostaglandin D2-glycerol ester reduces murine colitis via DP1 and PPARγ receptors.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29630407","citation_count":28,"is_preprint":false},{"pmid":"30657780","id":"PMC_30657780","title":"Structure of the DP1-DP2 PolD complex bound with DNA and its implications for the evolutionary history of DNA and RNA polymerases.","date":"2019","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/30657780","citation_count":28,"is_preprint":false},{"pmid":"8788032","id":"PMC_8788032","title":"Expression of the E2F-1/DP-1 transcription factor in murine development.","date":"1996","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/8788032","citation_count":28,"is_preprint":false},{"pmid":"11429786","id":"PMC_11429786","title":"Deregulated expression of DP1 induces epidermal proliferation and enhances skin carcinogenesis.","date":"2001","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/11429786","citation_count":27,"is_preprint":false},{"pmid":"29621586","id":"PMC_29621586","title":"Long non-coding RNA DILC suppresses cell proliferation and metastasis in colorectal cancer.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/29621586","citation_count":27,"is_preprint":false},{"pmid":"29449194","id":"PMC_29449194","title":"Prostaglandin D2 Receptor DP1 Antibodies Predict Vaccine-induced and Spontaneous Narcolepsy Type 1: Large-scale Study of Antibody Profiling.","date":"2018","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/29449194","citation_count":26,"is_preprint":false},{"pmid":"30893431","id":"PMC_30893431","title":"Role of the L-PGDS-PGD2-DP1 receptor axis in sleep regulation and neurologic outcomes.","date":"2019","source":"Sleep","url":"https://pubmed.ncbi.nlm.nih.gov/30893431","citation_count":24,"is_preprint":false},{"pmid":"15448153","id":"PMC_15448153","title":"The DP-1 transcription factor is required for keratinocyte growth and epidermal stratification.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15448153","citation_count":24,"is_preprint":false},{"pmid":"9556576","id":"PMC_9556576","title":"The p53 tumor suppressor inhibits transcription of the TATA-less mouse DP1 promoter.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9556576","citation_count":24,"is_preprint":false},{"pmid":"15121900","id":"PMC_15121900","title":"Characterization of the 3' exonuclease subunit DP1 of Methanococcus jannaschii replicative DNA polymerase D.","date":"2004","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/15121900","citation_count":24,"is_preprint":false},{"pmid":"6146601","id":"PMC_6146601","title":"Biochemical characterization of a murein hydrolase induced by bacteriophage Dp-1 in Streptococcus pneumoniae: comparative study between bacteriophage-associated lysin and the host amidase.","date":"1984","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/6146601","citation_count":24,"is_preprint":false},{"pmid":"20973774","id":"PMC_20973774","title":"Co-operative signalling through DP(1) and DP(2) prostanoid receptors is required to enhance leukotriene C(4) synthesis induced by prostaglandin D(2) in eosinophils.","date":"2011","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20973774","citation_count":24,"is_preprint":false},{"pmid":"19007903","id":"PMC_19007903","title":"Central prostaglandin D(2) exhibits anxiolytic-like activity via the DP(1) receptor in mice.","date":"2008","source":"Prostaglandins & other lipid mediators","url":"https://pubmed.ncbi.nlm.nih.gov/19007903","citation_count":23,"is_preprint":false},{"pmid":"6132961","id":"PMC_6132961","title":"A phage-associated murein hydrolase in Streptococcus pneumoniae infected with bacteriophage Dp-1.","date":"1983","source":"Journal of general microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/6132961","citation_count":23,"is_preprint":false},{"pmid":"18243414","id":"PMC_18243414","title":"Rubimetide (Met-Arg-Trp) derived from Rubisco exhibits anxiolytic-like activity via the DP1 receptor in male ddY mice.","date":"2007","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/18243414","citation_count":23,"is_preprint":false},{"pmid":"8655653","id":"PMC_8655653","title":"Regulation of transcription by E2F1/DP1.","date":"1995","source":"Journal of cell science. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/8655653","citation_count":22,"is_preprint":false},{"pmid":"15282318","id":"PMC_15282318","title":"Dp1 is largely dispensable for embryonic development.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15282318","citation_count":22,"is_preprint":false},{"pmid":"15863509","id":"PMC_15863509","title":"Identification and characterization of novel isoforms of human DP-1: DP-1{alpha} regulates the transcriptional activity of E2F1 as well as cell cycle progression in a dominant-negative manner.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15863509","citation_count":22,"is_preprint":false},{"pmid":"9989809","id":"PMC_9989809","title":"Association with E2F-1 governs intracellular trafficking and polyubiquitination of DP-1.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9989809","citation_count":21,"is_preprint":false},{"pmid":"30716440","id":"PMC_30716440","title":"Long non-coding RNA DILC promotes the progression of gallbladder carcinoma.","date":"2019","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30716440","citation_count":20,"is_preprint":false},{"pmid":"27802335","id":"PMC_27802335","title":"E2F1 and TFDP1 Regulate PITX1 Expression in Normal and Osteoarthritic Articular Chondrocytes.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27802335","citation_count":20,"is_preprint":false},{"pmid":"18687693","id":"PMC_18687693","title":"SOCS-3 inhibits E2F/DP-1 transcriptional activity and cell cycle progression via interaction with DP-1.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18687693","citation_count":20,"is_preprint":false},{"pmid":"7951410","id":"PMC_7951410","title":"Regulation of adenovirus 12 E1A transcription: E2F and ATF motifs in the E1A promoter bind nuclear protein complexes including E2F1, DP-1, cyclin A and/or RB and mediate transcriptional (auto)activation.","date":"1993","source":"Cellular & molecular biology research","url":"https://pubmed.ncbi.nlm.nih.gov/7951410","citation_count":20,"is_preprint":false},{"pmid":"37141667","id":"PMC_37141667","title":"The TFDP1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F.","date":"2023","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/37141667","citation_count":19,"is_preprint":false},{"pmid":"21036609","id":"PMC_21036609","title":"Potent and highly selective DP1 antagonists with 2,3,4,9-tetrahydro-1H-carbazole as pharmacophore.","date":"2010","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/21036609","citation_count":19,"is_preprint":false},{"pmid":"10778981","id":"PMC_10778981","title":"Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.","date":"2000","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/10778981","citation_count":19,"is_preprint":false},{"pmid":"28378369","id":"PMC_28378369","title":"A randomized controlled phase II clinical trial comparing ONO-4053, a novel DP1 antagonist, with a leukotriene receptor antagonist pranlukast in patients with seasonal allergic rhinitis.","date":"2017","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/28378369","citation_count":18,"is_preprint":false},{"pmid":"30365067","id":"PMC_30365067","title":"Long non‑coding RNA DILC is involved in sepsis by modulating the signaling pathway of the interleukin‑6/signal transducer and activator of transcription 3/Toll‑like receptor 4 axis.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30365067","citation_count":18,"is_preprint":false},{"pmid":"38361031","id":"PMC_38361031","title":"Genome-wide ATAC-see screening identifies TFDP1 as a modulator of global chromatin accessibility.","date":"2024","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38361031","citation_count":17,"is_preprint":false},{"pmid":"35212626","id":"PMC_35212626","title":"KDM6B interacts with TFDP1 to activate P53 signaling in regulating mouse palatogenesis.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35212626","citation_count":17,"is_preprint":false},{"pmid":"23762421","id":"PMC_23762421","title":"Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23762421","citation_count":17,"is_preprint":false},{"pmid":"27009856","id":"PMC_27009856","title":"mTOR regulates proteasomal degradation and Dp1/E2F1- mediated transcription of KPNA2 in lung cancer cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27009856","citation_count":17,"is_preprint":false},{"pmid":"26277322","id":"PMC_26277322","title":"Effect of the potent and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of allergic rhinitis and allergic asthma.","date":"2015","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26277322","citation_count":17,"is_preprint":false},{"pmid":"9074408","id":"PMC_9074408","title":"The predominant E2F complex in human primary haemopoietic cells and in AML blasts contains E2F-4, DP-1 and p130.","date":"1997","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/9074408","citation_count":17,"is_preprint":false},{"pmid":"23103473","id":"PMC_23103473","title":"Nicotinic acid and DP1 blockade: studies in mouse models of atherosclerosis.","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23103473","citation_count":16,"is_preprint":false},{"pmid":"34920958","id":"PMC_34920958","title":"Protectin DX promotes the inflammatory resolution via activating COX-2/L-PGDS-PGD2 and DP1 receptor in acute respiratory distress syndrome.","date":"2021","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34920958","citation_count":16,"is_preprint":false},{"pmid":"25218962","id":"PMC_25218962","title":"PGD2 DP1 receptor stimulation following stroke ameliorates cerebral blood flow and outcomes.","date":"2014","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25218962","citation_count":15,"is_preprint":false},{"pmid":"29607536","id":"PMC_29607536","title":"DP1 receptor signaling prevents the onset of intrinsic apoptosis in eosinophils and functions as a transcriptional modulator.","date":"2018","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/29607536","citation_count":15,"is_preprint":false},{"pmid":"25940086","id":"PMC_25940086","title":"Kelch Repeat and BTB Domain Containing Protein 5 (Kbtbd5) Regulates Skeletal Muscle Myogenesis through the E2F1-DP1 Complex.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25940086","citation_count":15,"is_preprint":false},{"pmid":"17141215","id":"PMC_17141215","title":"Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice.","date":"2006","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17141215","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52659,"output_tokens":8257,"usd":0.140916},"stage2":{"model":"claude-opus-4-6","input_tokens":12125,"output_tokens":3788,"usd":0.232987},"total_usd":0.373903,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"Human DP-1 (TFDP1) heterodimerizes with E2F-1 both in vivo and in vitro, and this heterodimer leads to enhanced binding to E2F DNA-binding sites and cooperative trans-activation of E2F-responsive promoters; the heterodimer is also required for stable interaction with pRB in vivo, and pRB inhibits transcriptional activity of the E2F-1/DP-1 complex.\",\n      \"method\": \"Co-immunoprecipitation (in vivo and in vitro), DNA-binding assays, trans-activation reporter assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (Co-IP, DNA-binding, transcriptional assays), replicated across multiple labs\",\n      \"pmids\": [\"8405995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"DP-1 (TFDP1) is a major sequence-specific DNA-binding component of the DRTF1/E2F transcription factor complex, including Rb- and p107-associated forms; its DNA-binding domain resembles that of E2F-1 and recognizes the same sequence.\",\n      \"method\": \"cDNA cloning, DNA-affinity purification, EMSA\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — original isolation and characterization with multiple orthogonal methods\",\n      \"pmids\": [\"8446173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"DP-1 and E2F-1 exist as a heterodimeric DNA-binding complex in vivo, bind preferentially as a heterodimer to the E2F site, and interact synergistically in E2F site-dependent transcriptional activation in yeast and Drosophila cells.\",\n      \"method\": \"Co-immunoprecipitation, EMSA, transcriptional assays in yeast and Drosophila\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods across organisms, replicated\",\n      \"pmids\": [\"8223441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"DP-1 undergoes cell cycle-regulated phosphorylation with a phosphorylation-dependent mobility shift; a C-terminal region of DP-1 interacts with pRb and contributes to pRb binding efficiency in the context of the DP-1/E2F-1 heterodimer; the DP-1/E2F-1 heterodimer specifically interacts with adenovirus E4 orf 6/7 protein to produce cooperative DNA binding at two E2F sites.\",\n      \"method\": \"Immunoprecipitation, phosphopeptide analysis, in vitro binding assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods, direct in vitro and in vivo demonstration\",\n      \"pmids\": [\"8039504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Cyclin A/CDK2 binds directly to E2F-1 (but not to DP-1) and phosphorylates the E2F-1/DP-1 complex, inhibiting its DNA-binding activity; the complex of cyclin A/CDK2 can be reconstituted from purified components with E2F-1/DP-1.\",\n      \"method\": \"In vitro reconstitution, kinase assay, in vitro and in vivo binding assays, 2D tryptic phosphopeptide mapping\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution from purified components plus in vivo corroboration\",\n      \"pmids\": [\"7969176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Heterodimerization of E2F-1 and DP-1 is required for stable binding to adenovirus E4 (ORF6/7) protein; pRb binding to E2F-1/DP-1 prevents the formation of an E2F-1/DP-1/E4 complex; the interaction with E4 requires the C-terminal 20 amino acids of E4 and E2F-1 residues 284–358.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assays, domain mapping/mutagenesis\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — domain mapping with mutagenesis and multiple binding assays\",\n      \"pmids\": [\"8035503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The hydrophobic heptad repeat domain of DP-1 (amino acids 196–245) mediates heterodimerization with E2F-1's corresponding domain (amino acids 206–283); adenovirus E4 protein directly contacts the DP-1 hydrophobic heptad repeat domain and can dimerize, bridging two E2F-1/DP-1 heterodimers at the E2 promoter.\",\n      \"method\": \"Yeast two-hybrid assay, co-immunoprecipitation, domain mapping\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — yeast two-hybrid and co-IP with defined domain mapping\",\n      \"pmids\": [\"8207796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The same internal domains of E2F-1 and DP-1 required for E4-6/7 binding are also required for stable interaction with Rb, and E4-6/7 and Rb binding to E2F-1/DP-1 are mutually exclusive.\",\n      \"method\": \"In vitro binding assays, domain deletion mapping\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct in vitro binding with systematic domain mapping\",\n      \"pmids\": [\"7933066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"MDM2 makes functional contact with both E2F1 and DP1 using residues conserved with the p53 activation domain; in contrast to its repression of p53, MDM2 stimulates the transcriptional activation capacity of E2F1/DP1.\",\n      \"method\": \"Co-immunoprecipitation, transcriptional activation assays, domain mapping\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct binding and functional assays, published in Nature\",\n      \"pmids\": [\"7791903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"E2F-1 and DP-1 physically complex with p53 both in vitro and in vivo; expression of both E2F1 and DP1 can inhibit p53-dependent transcription independently of MDM2, while wild-type p53 can inhibit E2F transcriptional activity.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, transcriptional assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with in vitro and in vivo validation\",\n      \"pmids\": [\"8557038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"E2F-1/DP-1 co-overexpression leads to greater loss of G1 regulation and significantly more apoptosis than E2F-1 alone; co-expression of DP-1 with E2F-1 increases endogenous p53 levels and overrides survival factors; induction of E2F-1/DP-1 increases expression and activity of cyclins A and E, and CDK2.\",\n      \"method\": \"Inducible expression, flow cytometry, apoptosis assays, immunoblotting\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — defined phenotypic readout with mechanistic targets identified\",\n      \"pmids\": [\"8524253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CBP co-activator directly contacts the activation domain of E2F1 both in vitro and in vivo and stimulates E2F1/DP1 transcriptional activity; CBP-induced activation is abolished by E1A N-terminus competitor but not by CBP-binding-deficient E1A mutant.\",\n      \"method\": \"In vitro binding assay, co-immunoprecipitation, transcriptional assays, squelching experiments\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct binding demonstrated both in vitro and in vivo with functional validation\",\n      \"pmids\": [\"8932363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"DP-1 mutants that retain E2F binding but lose DNA binding arrest cells in G1 by forming transcriptionally inactive E2F complexes; this G1 arrest can be rescued by co-expression of wild-type E2F or DP; functional domains of DP-1 required for dimerization and DNA binding were separated.\",\n      \"method\": \"Dominant-negative mutant transfection, flow cytometry, rescue experiments\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — dominant-negative approach with clear phenotypic readout and rescue, defining functional domains\",\n      \"pmids\": [\"8668186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"DP-1 associates with p53 in mammalian cell extracts; in vitro p53 interacts with an immunochemically distinct form of DP-1; p53 competes with E2F-1 for DP-1 binding, reducing DNA binding activity; a C-terminal region of DP-1 is required for the interaction with p53, and an N-terminal region of p53 distinct from that required for MDM2 binding is responsible.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assays, domain mutagenesis, EMSA\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro and in vivo binding plus domain mutagenesis\",\n      \"pmids\": [\"8816502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Induction of E2F-1/DP-1 results in increased expression and activity of cyclins A and E, and CDK2 prior to S-phase entry; increased phosphorylation of Rb follows, suggesting E2F feeds back on Rb; DP-1 alone (even with a VP16 transactivation domain) fails to promote cell cycle entry.\",\n      \"method\": \"Inducible expression system, immunoblotting, kinase assays, flow cytometry\",\n      \"journal\": \"Cell growth & differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic inducible expression with mechanistic target analysis\",\n      \"pmids\": [\"8780882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"p202, an interferon-inducible protein, inhibits E2F-4/DP-1-stimulated transcription; p202 associates with E2F-4 and pocket proteins p107 and p130, and inhibits sequence-specific DNA binding of E2F-4 both in complex with pocket proteins and in its free form.\",\n      \"method\": \"Transcriptional reporter assays, in vitro and in vivo binding assays, EMSA\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — single study with in vitro and in vivo binding and functional assays\",\n      \"pmids\": [\"9233764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"p53 inhibits transcription driven by the TFDP1 (DP-1) TATA-less promoter at the transcriptional level, with relative specificity for the DP1 promoter compared to the E2F1 promoter or unrelated promoters.\",\n      \"method\": \"Reporter gene assays, promoter deletion analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, functional assay but limited mechanistic follow-up\",\n      \"pmids\": [\"9556576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Association of DP-1 with E2F subunits governs intracellular trafficking: DP-1 polypeptides that bind E2F-1 enter the nucleus, whereas those failing to associate with E2F accumulate in the cytoplasm as polyubiquitinated DP-1; E2F-1 binding prevents ubiquitin-dependent cytoplasmic degradation of DP-1.\",\n      \"method\": \"Immunolocalization, immunoprecipitation, cell fractionation, inducible expression\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (fractionation, Co-IP, localization) with functional consequence\",\n      \"pmids\": [\"9989809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TRIP-Br1 and TRIP-Br2 proteins contact DP-1 and stimulate E2F-1/DP-1 transcriptional activity; TRIP-Br1 is a component of a multiprotein complex containing E2F-1 and DP-1; KRIP-1 potentiates TRIP-Br co-activation of E2F-1/DP-1; RB abolishes both baseline E2F-1/DP-1 activity and TRIP-Br co-activation.\",\n      \"method\": \"Co-immunoprecipitation, transcriptional assays, protein complex analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP and transcriptional assays with multiple components\",\n      \"pmids\": [\"11331592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Deregulated expression of DP-1 in mouse basal layer keratinocytes caused epidermal hyperplasia and hyperproliferation, and enhanced skin carcinogenesis in a two-stage chemical carcinogenesis assay; co-expression with E2F1 or E2F4 modestly enhanced proliferation and apoptosis.\",\n      \"method\": \"Transgenic mouse model, histology, two-stage carcinogenesis assay\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic model with defined phenotypic readout\",\n      \"pmids\": [\"11429786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ARF relocalizes DP-1 from the cytoplasm to the nucleolus when DP-1 is alone; however, the E2F1/DP-1 heterodimer is refractory to ARF-induced relocalization and remains in the nucleoplasm; ARF does not interact with the E2F1/DP-1 complex, and E2F1 is more stable in the presence of ARF when co-expressed with DP-1.\",\n      \"method\": \"Immunofluorescence localization, co-immunoprecipitation, stability assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including localization and stability assays\",\n      \"pmids\": [\"12446760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Loss of Dp1 in mice leads to embryonic lethality due to failure of extra-embryonic (trophectoderm-derived) tissue development; specifically, expansion of the ectoplacental cone and chorion fail, and endoreduplication in trophoblast giant cells is compromised; inactivation of p53 cannot rescue Dp1-deficient embryonic lethality.\",\n      \"method\": \"Dp1 knockout mouse, histology, genetic rescue experiments\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mouse knockout with defined cellular phenotype and epistasis test\",\n      \"pmids\": [\"12588846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"DP-1 activity is required for normal epidermal morphogenesis and ectoderm-to-epidermis transition; dominant-negative DP-1 inhibits E2F/DP-1 heterodimer DNA binding, DNA replication, and cyclin A expression; ChIP showed cyclin A promoter is bound predominantly by E2F-3 and E2F-4 complexes in proliferating keratinocytes.\",\n      \"method\": \"Dominant-negative expression in organotypic culture and embryonic explants, ChIP, immunoblotting\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — chromatin immunoprecipitation with functional dominant-negative assays and phenotypic readout\",\n      \"pmids\": [\"15448153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Dp1-deficient embryonic stem cells can contribute strongly to most chimeric tissues, indicating that Dp1 is largely dispensable for embryonic (but not extraembryonic) development; abundance of DP2 protein does not increase in Dp1-deficient ES cells, and expression of an array of cell cycle genes is virtually unchanged.\",\n      \"method\": \"Chimeric mouse analysis, X-Gal staining, Western blotting, gene expression analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic chimeric analysis with molecular characterization\",\n      \"pmids\": [\"15282318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The crystal structure of an RbC–E2F1–DP1 complex reveals an intertwined heterodimer in which the marked box domains of both E2F1 and DP1 contact the Rb C-terminal domain (RbC); phosphorylation of RbC at S788/S795 directly destabilizes RbC–E2F/DP interactions, while phosphorylation at T821/T826 induces an intramolecular RbC–Rb pocket interaction that indirectly destabilizes the remaining contacts.\",\n      \"method\": \"X-ray crystallography, biochemical binding assays with phosphorylation-site mutants\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with phosphorylation-site mutagenesis and functional validation\",\n      \"pmids\": [\"16360038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Two novel isoforms of human DP-1 (DP-1α and DP-1β) were identified; DP-1α lacks a portion of the C-terminal heterodimerization domain, shows significantly reduced binding to E2F1, does not translocate to the nucleus with E2F1, and acts as a dominant-negative regulator causing decreased transcriptional activity and G1 cell cycle arrest.\",\n      \"method\": \"Yeast two-hybrid, immunoprecipitation, immunofluorescence, transcriptional assays, flow cytometry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods establishing isoform-specific mechanism\",\n      \"pmids\": [\"15863509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ARF directly binds DP-1, and this binding inhibits the interaction between DP-1 and E2F1; ARF regulates DP-1 association with the dhfr target gene promoter (by ChIP); S-phase inhibition by ARF is preceded by inhibition of E2F-activated genes and occurs independently of p53 and Mdm2; the ARF–DP1 interaction is enhanced during oncogenic stress.\",\n      \"method\": \"Direct binding assay (GST pulldown), co-immunoprecipitation, ChIP, cell cycle analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct binding assay plus ChIP plus functional cell cycle readout\",\n      \"pmids\": [\"16135794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SOCS-3 directly interacts with the C-terminal region of DP-1 (requiring SOCS-3 residues 156–172) and is co-localized with DP-1 primarily in the cytoplasm; SOCS-3 inhibits E2F/DP-1 transcriptional activity under the cyclin-E promoter, inhibiting cell cycle progression; conversely, DP-1 almost completely abolishes the inhibitory action of SOCS-3 on JAK-STAT signaling.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, confocal microscopy, transcriptional assays, siRNA knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — yeast two-hybrid + co-IP + functional assays with domain mapping\",\n      \"pmids\": [\"18687693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Cdk5 (in complex with p35) forms a complex with E2F1, excluding DP-1 cofactor from E2F1, thereby inhibiting E2F1 binding to promoters of cell cycle genes and suppressing cell cycle re-entry in post-mitotic neurons; this function does not require Cdk5 enzymatic activity.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation, kinase-dead mutant analysis\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP and ChIP demonstrating complex formation and exclusion of DP-1\",\n      \"pmids\": [\"20392944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Adenovirus E1A 13S isoform directly binds DP-1 and uses this interaction to recruit itself to E2F-regulated promoters, activating E2F-responsive gene expression independently of pRb-family binding; this binding is through a direct interaction with DP-1 (not E2F), and E1A 13S (but not 12S) enhances E2F4 occupancy at E2F sites.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, reporter assays, domain mapping\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding demonstrated with ChIP and functional transcriptional assays\",\n      \"pmids\": [\"21715488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Kbtbd5 directly interacts with DP-1 (via its dimerization domain) and promotes ubiquitination and degradation of DP-1, thereby inhibiting E2F1-DP-1 transcriptional activity; loss of Kbtbd5 in mice causes increased E2F1 target gene expression and apoptosis in skeletal muscle; breeding into E2F1 null background rescues the lethal phenotype.\",\n      \"method\": \"Yeast two-hybrid, GST pulldown, ubiquitination assay, knockout mouse, genetic epistasis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct binding assay + ubiquitination assay + genetic epistasis in vivo\",\n      \"pmids\": [\"25940086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"COMMD9 interacts with TFDP1 through its COMM domain, requiring the DNA-binding domain of TFDP1; COMMD9 knockdown attenuates TFDP1/E2F1 transcriptional activity and enhances p53 signaling in NSCLC cells.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, transcriptional assays\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP with functional assays but single lab, single binding method\",\n      \"pmids\": [\"27871936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Knockdown of TFDP1 inhibits E2F1-mediated PITX1 promoter activity and mRNA transcription in articular chondrocytes; E2F1 directly binds GC-rich elements in the PITX1 promoter; TFDP1 knockdown reduces expression of PITX1, BRCA1, CDKN1A, and RAD51 in mid-stage OA chondrocytes.\",\n      \"method\": \"siRNA knockdown, luciferase reporter assay, ChIP, DNA pulldown, qRT-PCR\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown combined with ChIP and promoter assays\",\n      \"pmids\": [\"27802335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"KPNA2 (karyopherin α2) imports E2F1 and TFDP1 into the nucleus; upon KPNA2 knockdown, E2F1 and TFDP1 are retained in the cytoplasm, leading to reduced STMN1 (stathmin) expression; the KPNA2–E2F1/TFDP1–STMN1 axis regulates tumor cell migration and colony formation in HCC.\",\n      \"method\": \"siRNA knockdown, subcellular fractionation, co-immunoprecipitation, ChIP, proteomics (LC-MS/MS)\",\n      \"journal\": \"Cell communication and signaling : CCS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — proteomic screen + fractionation + Co-IP + ChIP demonstrating nuclear transport mechanism\",\n      \"pmids\": [\"31783876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"KDM6B (an H3K27me3 demethylase) interacts with TFDP1, which normally binds to the promoter of Trp53 to activate Trp53 expression in palatal mesenchymal cells; without KDM6B, TFDP1 cannot activate Trp53, leading to complete cleft palate; H3K27me3 on the Trp53 promoter is antagonistically controlled by KDM6B and EZH2.\",\n      \"method\": \"Conditional knockout mouse, ChIP, co-immunoprecipitation, promoter analysis, histology\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with ChIP and protein interaction data demonstrating mechanism\",\n      \"pmids\": [\"35212626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The TFDP1 gene is a target of deregulated E2F1: overexpression of E2F1 and pRb inactivation (by adenovirus E1a) induce TFDP1 gene expression in normal fibroblasts; deregulated (but not physiological) E2F1 binds GC-rich elements in the TFDP1 promoter (by ChIP); DP1 knockdown enhances ARF gene expression, suggesting TFDP1 induction by deregulated E2F acts as a failsafe feedback mechanism.\",\n      \"method\": \"E2F1 overexpression, adenovirus E1a, promoter deletion analysis, ChIP, shRNA knockdown, qRT-PCR\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus promoter mutagenesis plus functional knockdown, defining a regulatory circuit\",\n      \"pmids\": [\"37141667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Genome-wide CRISPR/ATAC-see screening identified TFDP1 as a modulator of global chromatin accessibility; TFDP1 knockout reduces chromatin accessibility by transcriptionally regulating canonical histones.\",\n      \"method\": \"Genome-wide CRISPR screen, ATAC-see, ATAC-seq, TFDP1 knockout\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide unbiased screen with ATAC-seq validation and KO mechanistic follow-up\",\n      \"pmids\": [\"38361031\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TFDP1 encodes DP-1, which obligatorily heterodimerizes with E2F-family proteins (primarily through hydrophobic heptad repeat and marked box domains) to form the active E2F/DP-1 transcription factor complex; this complex binds E2F DNA sites to activate S-phase genes (cyclins A/E, CDK2, DHFR, etc.) and is regulated by pRb (which directly contacts both E2F1 and DP-1 marked box domains to repress activity), cyclin A/CDK2 phosphorylation (which inhibits DNA binding), ARF (which directly binds free DP-1 to disrupt E2F1/DP-1 heterodimerization), ubiquitin-mediated degradation (prevented by E2F-1 association, which promotes nuclear entry), co-activators (CBP, MDM2, TRIP-Br), and co-repressors (p53, SOCS-3, p202); nuclear import of the E2F1/TFDP1 complex is mediated by KPNA2, and TFDP1 itself is transcriptionally induced by deregulated E2F1 as a feedback mechanism; additionally, TFDP1 modulates global chromatin accessibility through transcriptional regulation of canonical histones.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TFDP1 encodes the transcription factor DP-1, an obligate heterodimerization partner of E2F-family proteins that together form the sequence-specific DNA-binding E2F/DP complex governing S-phase gene expression and cell cycle progression [PMID:8405995, PMID:8446173, PMID:8223441]. Heterodimerization occurs through the hydrophobic heptad repeat and marked box domains; the resulting complex activates transcription of cyclins A and E, CDK2, and DHFR, and is negatively regulated by pRb (which contacts both E2F1 and DP-1 marked box domains), cyclin A/CDK2-mediated phosphorylation that inhibits DNA binding, ARF (which directly binds free DP-1 to disrupt E2F1/DP-1 heterodimerization independently of p53), and Kbtbd5-mediated ubiquitination and degradation of DP-1 [PMID:16360038, PMID:7969176, PMID:16135794, PMID:25940086]. Nuclear import of the E2F1/TFDP1 complex requires KPNA2, and unpartnered DP-1 is retained in the cytoplasm and targeted for ubiquitin-dependent degradation [PMID:31783876, PMID:9989809]. Beyond canonical cell cycle gene regulation, TFDP1 modulates global chromatin accessibility through transcriptional control of canonical histones [PMID:38361031].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Identification of DP-1 as an obligate heterodimeric partner of E2F-1 resolved the long-standing question of how high-affinity, sequence-specific E2F DNA binding and transcriptional activation are achieved, and established that the resulting heterodimer is a target of pRb-mediated repression.\",\n      \"evidence\": \"Co-immunoprecipitation, EMSA, and transcriptional reporter assays in mammalian, yeast, and Drosophila cells\",\n      \"pmids\": [\"8405995\", \"8446173\", \"8223441\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and affinity of the heterodimer not quantified\", \"Whether DP-1 contributes transactivation function independently of E2F was unclear\", \"In vivo physiological requirement not yet tested\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Mapping the hydrophobic heptad repeat domain (DP-1 aa 196–245) as the heterodimerization interface and demonstrating cell-cycle-dependent DP-1 phosphorylation and cyclin A/CDK2-mediated inhibition of DNA binding defined the structural and regulatory logic governing E2F/DP activity.\",\n      \"evidence\": \"Yeast two-hybrid, domain deletion mapping, in vitro kinase assays with purified components, phosphopeptide analysis\",\n      \"pmids\": [\"8207796\", \"8039504\", \"7969176\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise phosphorylation sites on DP-1 responsible for DNA-binding inhibition not mapped\", \"Whether cyclin A/CDK2 phosphorylates DP-1 directly or only E2F-1 in the heterodimer was unresolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Discovery that MDM2 stimulates and p53 inhibits E2F1/DP-1 transcriptional activity, and that E2F-1/DP-1 overexpression induces p53 and apoptosis, placed the E2F/DP complex at the intersection of proliferation and apoptosis pathways.\",\n      \"evidence\": \"Co-immunoprecipitation, GST pulldown, transcriptional assays, inducible expression with flow cytometry and apoptosis measurement\",\n      \"pmids\": [\"7791903\", \"8557038\", \"8524253\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of MDM2 co-activation versus p53 repression not resolved in normal cells\", \"Whether DP-1 directly contacts MDM2 or p53 independently of E2F-1 needed clarification\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstration that dominant-negative DP-1 mutants retaining E2F binding but lacking DNA-binding activity arrest cells in G1, and that p53 directly competes with E2F-1 for DP-1 binding, established DP-1 as a rate-limiting factor for E2F-dependent S-phase entry.\",\n      \"evidence\": \"Dominant-negative transfection with flow cytometry, rescue experiments, domain mutagenesis, and EMSA competition assays\",\n      \"pmids\": [\"8668186\", \"8816502\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p53-DP-1 complex has a function beyond sequestration was unknown\", \"In vivo relevance of p53-DP-1 competition not tested genetically\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showing that E2F-1 binding rescues DP-1 from cytoplasmic polyubiquitination and promotes its nuclear entry revealed that subcellular partitioning and protein stability are coupled to heterodimerization status.\",\n      \"evidence\": \"Immunolocalization, cell fractionation, immunoprecipitation of ubiquitinated species, inducible expression\",\n      \"pmids\": [\"9989809\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The E3 ubiquitin ligase responsible for DP-1 cytoplasmic degradation was not identified\", \"Whether regulated deubiquitination plays a role was unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Dp1 knockout in mice causing embryonic lethality due to failed trophoblast expansion and endoreduplication — not rescued by p53 loss — demonstrated an essential, p53-independent developmental role for DP-1 in extra-embryonic tissues.\",\n      \"evidence\": \"Dp1 knockout mouse, histological analysis, p53 genetic rescue cross\",\n      \"pmids\": [\"12588846\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which E2F partner(s) mediate the extra-embryonic requirement was not determined\", \"Molecular targets of E2F/DP in endoreduplication not identified\", \"Why embryonic tissues tolerate Dp1 loss (later shown via chimera analysis) needed explanation\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Chimeric mouse analysis showing that Dp1-null ES cells contribute normally to most embryonic tissues, without compensatory DP-2 upregulation, revealed that DP-1 is largely dispensable for embryonic somatic cell proliferation, restricting its essential role to extra-embryonic lineages.\",\n      \"evidence\": \"Dp1-null ES cell chimeras, X-Gal staining, Western blot, expression profiling\",\n      \"pmids\": [\"15282318\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DP-2 functionally compensates despite unchanged protein levels was not formally tested\", \"Adult tissue-specific requirements not examined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The crystal structure of the RbC–E2F1–DP1 complex revealed that the marked box domains of both E2F1 and DP1 directly contact the Rb C-terminal domain, and phosphorylation at specific Rb sites destabilizes these contacts, providing an atomic-level mechanism for CDK-driven E2F/DP release.\",\n      \"evidence\": \"X-ray crystallography with phosphorylation-site mutagenesis and biochemical binding assays\",\n      \"pmids\": [\"16360038\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of full-length DP-1 or of DP-1 with other E2F family members not determined\", \"Dynamics of the release in vivo not captured\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Direct binding of ARF to DP-1 that disrupts E2F1/DP-1 heterodimerization independently of p53/Mdm2, and identification of dominant-negative DP-1 isoforms (DP-1α), defined two distinct mechanisms that restrain E2F/DP activity by targeting DP-1 availability.\",\n      \"evidence\": \"GST pulldown, ChIP at dhfr promoter, cell cycle analysis in p53-null cells; yeast two-hybrid and immunofluorescence for isoform characterization\",\n      \"pmids\": [\"16135794\", \"15863509\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological abundance and tissue distribution of DP-1α isoform unknown\", \"Whether ARF-DP-1 binding occurs at specific genomic loci genome-wide not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of Kbtbd5 as a direct E3 ligase adapter that ubiquitinates DP-1 via its dimerization domain, with genetic epistasis showing that Kbtbd5-null lethality is rescued by E2F1 loss, established a tissue-specific ubiquitin-dependent mechanism controlling E2F/DP activity in skeletal muscle.\",\n      \"evidence\": \"Yeast two-hybrid, GST pulldown, ubiquitination assay, Kbtbd5 knockout mouse, E2F1-null genetic rescue\",\n      \"pmids\": [\"25940086\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Kbtbd5 acts as the Cullin adapter or a direct RING E3 was not fully clarified\", \"Other tissues regulated by Kbtbd5-DP-1 axis not explored\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstration that KPNA2 mediates nuclear import of the E2F1/TFDP1 complex, with KPNA2 depletion causing cytoplasmic retention and loss of target gene (STMN1) expression, defined the nuclear transport pathway for E2F/DP.\",\n      \"evidence\": \"siRNA knockdown, subcellular fractionation, co-immunoprecipitation, ChIP, LC-MS/MS proteomics in HCC cells\",\n      \"pmids\": [\"31783876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether KPNA2 recognizes a classical NLS on E2F1, DP-1, or both was not mapped\", \"Redundancy with other karyopherin-α isoforms not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showing that deregulated E2F1 transcriptionally induces TFDP1 itself via GC-rich promoter elements, while DP-1 knockdown derepresses ARF, revealed a positive-feedback/failsafe circuit in which excessive E2F activity amplifies DP-1 but simultaneously triggers ARF-mediated restraint.\",\n      \"evidence\": \"E2F1 overexpression, adenovirus E1a, ChIP on TFDP1 promoter, shRNA knockdown, qRT-PCR in fibroblasts\",\n      \"pmids\": [\"37141667\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this feedback circuit operates in all cell types or is context-specific was not determined\", \"Quantitative thresholds for feedback engagement not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A genome-wide CRISPR/ATAC-see screen identified TFDP1 as a regulator of global chromatin accessibility beyond classical E2F target genes, acting through transcriptional control of canonical histone expression, expanding TFDP1's role from cell cycle gene regulation to a broader chromatin organizer.\",\n      \"evidence\": \"Genome-wide CRISPR screen, ATAC-see, ATAC-seq, TFDP1 knockout with expression analysis\",\n      \"pmids\": [\"38361031\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which E2F partner(s) cooperate with DP-1 for histone gene regulation not identified\", \"Whether reduced chromatin accessibility is a direct or indirect consequence of histone loss not fully resolved\", \"Impact on heterochromatin versus euchromatin domains not dissected\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full-length structure of DP-1 in complex with different E2F family members, the complete repertoire of E3 ligases targeting DP-1 across tissues, the genome-wide interplay between ARF-DP-1 and Rb-E2F/DP regulatory arms, and whether DP-1's chromatin accessibility function via histone regulation is separable from its canonical role in activating S-phase genes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length DP-1 structure available\", \"Tissue-specific E3 ligase landscape for DP-1 degradation uncharacterized\", \"Genome-wide ARF-DP-1 binding sites not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 2, 12, 22]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 10, 14, 32, 36]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [17, 20, 33]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [17, 20, 27]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [17, 25, 33]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [10, 12, 14, 22, 26]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 11, 32, 35, 36]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [36]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [10, 30]}\n    ],\n    \"complexes\": [\n      \"E2F/DP heterodimer\",\n      \"E2F/DP/Rb complex\",\n      \"E2F/DP/p107 complex\"\n    ],\n    \"partners\": [\n      \"E2F1\",\n      \"RB1\",\n      \"CDKN2A\",\n      \"KPNA2\",\n      \"MDM2\",\n      \"TP53\",\n      \"KBTBD5\",\n      \"SOCS3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}